Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trappsol Cyclo in Niemann-Pick Disease Type C1
NCT02912793Phase 2Completed
- Sponsor
- Cyclo Therapeutics, Inc.
- Start
- Mar 2017
- Primary completion
- Mar 2021
- Modality
- Nanoparticles, Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of Trappsol Cyclo in Niemann-Pick disease type C1 (NPC1) (3 arms), sponsored by Cyclo Therapeutics, Inc. Primary endpoints: Maximum Plasma Concentration at 20 hours, Time to Maximum Concentration at 20 hours and 2 more. Started Mar 2017; status: completed.
02
Drugs
Trappsol Cyclo
03
Conditions
Niemann-Pick disease type C1 (NPC1)
Beyond the preview
Go deeper on NCT02912793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912793.